Mednet Logo

How do you sequence abiraterone and enzalutamide in metastatic, castrate-resistant prostate cancer?

What determines which you select first? How do concerns about cross-resistance factor in after progression on one of these agents?
3 Answers
Mednet Member
Mednet MemberInvited Expert
Medical Oncology · Cleveland Clinic
Answered on

In my experience, abiraterone is better tolerated than enzalutamide. The main difference is fatigue. Quality of life seems no different to most of my patients when I add abiraterone to a GnRH agonist. However, patients frequently complain of substantially increased fatigue with the addition of enzal...

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Medical Oncology · Duke University School of Medicine
Answered on

Both abiraterone and enzalutamide appear equally effective in delaying progression and improving survival in chemo-naive men. The choice of front line therapy therefore becomes more related to side effects, cost, and tolerability long term, as many of these men will take abi or enza for several year...

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Medical Oncology · Cedars-Sinai Medical Center
Answered on

There have been biomarker studies suggesting that it is possible to identify men who are better suited for abiraterone therapy. Charles Ryan has shown that DHEA concentration is informative as low levels suggest a lack of androgen biosynthesis drive and more strongly justify direct inhibition of the...

Join for free or sign in to see the full answer